TY - JOUR
T1 - Everolimus in kidney transplant recipients at high cardiovascular risk
T2 - a narrative review
AU - ENTROPIA Project
AU - Paoletti, Ernesto
AU - Citterio, Franco
AU - Corsini, Alberto
AU - Potena, Luciano
AU - Rigotti, Paolo
AU - Sandrini, Silvio
AU - Bussalino, Elisabetta
AU - Stallone, Giovanni
AU - Ambrosini, Andrea
AU - Arnaboldi, Lorenzo
AU - Bellino, Diego
AU - Boschiero, Luigi
AU - Caldara, Rossana
AU - Cannone, Manuela
AU - Carmellini, Mario
AU - Carrano, Rosa
AU - Manuelli, Matteo Ciancio
AU - De Cicco, Marco
AU - De Rosa, Paride
AU - Federico, Stefano
AU - Garosi, Guido
AU - Iappelli, Massimo
AU - Iaria, Giuseppe
AU - Mastrosimone, Stefania
AU - Minetti, Enrico Eugenio
AU - Piotti, Giovanni
AU - Piredda, Gianbenedetto
AU - Pisani, Franco
AU - Poli, Luca
AU - Pretagostini, Renzo
AU - Pulizzi, Roberto
AU - Rampino, Teresa
AU - Ranghino, Andrea
AU - Sabbatini, Massimo
AU - Saracino, Angelo
AU - Todeschini, Paola
AU - Vicedomini, Daniela
AU - Vinti, Valentina
AU - Zaza, Gianluigi
N1 - Funding Information:
We thank Gayle Robins, independent medical writer, who provided editorial assistance and journal styling services prior to submission on behalf of Springer Healthcare Communications. Editorial services were funded by Novartis Farma, Italy. Collaborators We would like to thank experts in the field of transplantation who participated in the round-table discussions of the ENTROPIA Project: Andrea Ambrosini, Azienda Ospedaliera Fondazione Macchi, Varese, Italy; Lorenzo Arnaboldi, Department of Pharmacological and Biomolecular Sciences, Universit? degli Studi di Milano, Milan, Italy.
Publisher Copyright:
© 2019, Italian Society of Nephrology.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Kidney transplant recipients (KTRs) are at increased risk of cardiovascular (CV) morbidity and mortality, and side effects induced by immunosuppressive therapy may be a major contributor to this risk, together with traditional CV risk factors. Many strategies have been considered in order to reduce CV risk in KTRs, such as steroid and/or calcineurin inhibitor (CNI) minimization, but current data are inconclusive. The introduction of mammalian target of rapamycin (mTOR) inhibitors, the cornerstone of CNI minimization, in the immunosuppressive protocol may reduce both the incidence and severity of CNI-associated side effects; however, whether this strategy has an impact on CV risk after kidney transplantation needs to be evaluated. To this end, a panel of Italian experts in the field of transplantation was convened in a series of meetings to assess the current literature on the potential of the mTOR inhibitor everolimus as a cardioprotective agent. This narrative review summarizes the panel’s round-table discussions and provides recommendations for CV risk management in KTRs.
AB - Kidney transplant recipients (KTRs) are at increased risk of cardiovascular (CV) morbidity and mortality, and side effects induced by immunosuppressive therapy may be a major contributor to this risk, together with traditional CV risk factors. Many strategies have been considered in order to reduce CV risk in KTRs, such as steroid and/or calcineurin inhibitor (CNI) minimization, but current data are inconclusive. The introduction of mammalian target of rapamycin (mTOR) inhibitors, the cornerstone of CNI minimization, in the immunosuppressive protocol may reduce both the incidence and severity of CNI-associated side effects; however, whether this strategy has an impact on CV risk after kidney transplantation needs to be evaluated. To this end, a panel of Italian experts in the field of transplantation was convened in a series of meetings to assess the current literature on the potential of the mTOR inhibitor everolimus as a cardioprotective agent. This narrative review summarizes the panel’s round-table discussions and provides recommendations for CV risk management in KTRs.
KW - Calcineurin inhibitors
KW - Cardiovascular risk
KW - Everolimus
KW - Kidney transplant recipients
KW - mTOR inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85065021451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065021451&partnerID=8YFLogxK
U2 - 10.1007/s40620-019-00609-y
DO - 10.1007/s40620-019-00609-y
M3 - Review article
C2 - 31028549
AN - SCOPUS:85065021451
VL - 33
SP - 69
EP - 82
JO - Journal of Nephrology
JF - Journal of Nephrology
SN - 1121-8428
IS - 1
ER -